Crescent Biopharma, Inc. (CBIO) is a Healthcare · Biotechnology company listed on NASDAQ. Price $17.32 (+3.28%), Market cap $0.51B, 52-week low–high $0.16 ~ $26.98.
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
Financial statements, price targets, institutional (13F) holdings and related news for Crescent Biopharma, Inc. are updated in real time on BlackAll Trade.
Crescent Biopharma, Inc. trades at $17.32 (+3.28%). Real-time quotes and charts are available on BlackAll Trade.
Crescent Biopharma, Inc. has a market cap of about $0.51B.
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprieta